


Your Support & How It Was Used

FISCAL YEAR 2024 IMPACT REPORT
(JULY 1, 2023 – JUNE 30, 2024)

Our Strategy



PEOPLE
We fund the best scientists around the globe




BIOLOGY
We empower scientists to advance our understanding of the immune system



DATA
We integrate emerging technologies to fuel data-driven discovery

FINANCIAL SCALE

Investing in Cancer Immunotherapy Research



*“Immunotherapy is one of the most significant advances for treating cancer in the modern era. The field is what it is today because CRI continues to be laser-focused on **breakthrough immunotherapy research.**”*

– **James P. Allison, PhD**

2018 Nobel Laureate
The University of Texas MD Anderson Cancer Center
CRI Scientific Advisory Council Director

PROGRAM SCALE

Building a Community of Scientific Talent

32	7	5	5	3	1
POSTDOCTORAL FELLOWSHIPS*	CLIP AWARDS (Clinic and Laboratory Integration Program)	STARS (Scientists TAKing Risks)	TECHNOLOGY IMPACT AWARDS	CLINICAL INNOVATOR TRIALS	BIOINFORMATICS BOOTCAMP

*Includes 3 Fellowships to Promote Racial Diversity and 4 Immuno-Informatics Fellowships

OUR MISSION:

SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers.



Chi-Yun Wu, PhD
The David J. Gladstone Institutes

CRI Immuno-Informatics Fellow

Chi-Yun Wu, PhD, has developed a cutting-edge computational algorithm to map intricate interactions within tumor microenvironments. Her algorithm uncovers cellular programs and networks to shed light on how various cell types interact within colorectal tumors. Dr. Wu’s pioneering approach will pinpoint key interactions that influence patient outcomes that could have broad applications across different cancer types.

HUMAN SCALE

Bringing the Promise of Immunotherapy to More Patients



"Immunotherapy actually saved my life when I had no other options."
- Karen Peterson, Breast Cancer Survivor

29

CANCERS NOW TREATABLE WITH IMMUNOTHERAPY

45%

OF NEWLY DIAGNOSED PATIENTS 9 MILLION PEOPLE GLOBALLY Eligible for immunotherapy

13

NEW FDA APPROVALS



Gavin Dunn, MD, PhD
Massachusetts General Hospital

CRI Lloyd J. Old STAR

Gavin Peter Dunn, MD, PhD, is a neurosurgeon-scientist studying how the immune system responds to brain tumors, a largely uncharted area of cancer research. While immunotherapies have revolutionized treatment for certain cancers, they have yet to make a significant impact on brain tumors, partly due to the complex biology and unique barriers present in the brain. Recently, Dr. Dunn made a groundbreaking discovery, identifying a subset of immune cells that behave differently in brain tumors—a finding that could be leveraged for developing new therapies.

In addition to his research, Dr. Dunn is also developing personalized vaccines to treat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer. Using advanced sequencing technology, these vaccines target the unique features of each patient's tumor. Early clinical results are promising, showing that the vaccines can elicit a strong immune response. Dr. Dunn's efforts are laying the foundation for future clinical trials, offering renewed hope for patients facing this devastating disease.

CRI Postdoctoral Fellow

Pancreatic cancer is one of the most aggressive and deadly forms of cancer, with a grim prognosis and few effective treatment options. Its tumor environment cleverly evades the body's immune response, rendering many therapies ineffective—a challenge scientists are still working to fully understand. **Chiara Falcomatà, PhD, is at the forefront of research aimed at uncovering how pancreatic cancer cells**


outmaneuver the immune system. By identifying critical signals within tumors and blood, she is shedding light on pathways for earlier diagnosis and more effective treatments. Dr. Falcomatà's groundbreaking work has the potential to transform the way we approach this formidable disease, providing more hope for life-saving treatment breakthroughs for pancreatic cancer patients.




Chiara Falcomatà, PhD
Icahn School of Medicine at Mount Sinai

TRUST AND TRANSPARENCY

Investing in Impact



FY2024 TOTAL EXPENSES
Total Operating Expenses (unaudited) \$32.5MM



supports research and science, medical, and patient education

Ranked among the top 5% of U.S. Rated Charities



Learn more at cancerresearch.org